ESSO-ESPSO, ISPSM & AGOI 19 - 21 April 2019 R D Choksi Auditorium, Tata Memorial Hospital, Parel, Mumbai 3rd INTERNATIONAL COURSE WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER 5 CME Credit Points Awarded
29
Embed
ESSO-ESPSO, ISPSM & AGOI · peritoneal surface malignancies and to review important developments in fields of gynecological and colorectal cancers in last one year. The pre-conference
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
ESSO-ESPSO, ISPSM & AGOI
19 - 21 April 2019R D Choksi Auditorium,Tata Memorial Hospital, Parel, Mumbai
3rd INTERNATIONAL COURSE
WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY | COLORECTAL CANCER
5 CME Credit Points Awarded
Dr. Amita Maheshwari Organising Secretary
Dr. Sudeep Gupta Organising Chairman
Dr. Somashekhar SP Hon. Secretary, ISPSM
Dr. SVS Deo President, ISPSM
Dear Friends,rdIt is our pleasure to invite you to the 3 ESSO-ESPSO, ISPSM & AGOI International Course, Workshop &
Conference along with Year in Review in Gynecological and Colorectal malignancies, organized by the
Indian Society of Peritoneal Surface Malignancies (ISPSM) in collaboration with the Association of
Gynaecologic Oncologists of India (AGOI), from April, 19-21 at Tata Memorial Hospital, Mumbai
The scientific program has been carefully designed to present and discuss the most recent evidence in
peritoneal surface malignancies and to review important developments in fields of gynecological and
colorectal cancers in last one year. The pre-conference workshop will have a series of lectures covering
practical aspects of CRS & HIPEC followed by live surgical demonstration of CRS, HIPEC and PIPEC. The
first twenty delegates will also get an opportunity to get hands-on in wet lab.
The conference will feature keynote lectures, didactic sessions, panel discussions and satellite symposia.
Delegates will get a chance to meet and interact with renowned international and national faculty members.
The conference will also provide an opportunity to present original work during oral and poster presentation
sessions with exciting awards in both categories. The best oral and poster awardees will receive
international HIPEC travel fellowships to an European Centre under the guidance of an international faculty.
This conference is intended for gynecological, surgical and medical oncologists, oncology nurses and
technicians, perfusionists, pathologists and other healthcare professionals working in the field of
gynecological and gastrointestinal cancers.
We look forward to your active participation & support in making this meeting successful.
Regards
Dr. Shalini Rajaram President, AGOI
Dr. Avanish Saklani Co-organising Secretary
Dr. Manish Bhandare & Dr. Vikram Chaudhari Workshop Co-ordinators
rd3 INTERNATIONAL COURSE
WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY COLORECTAL CANCER
19 - 21 April 2019, Mumbai
1
Live surgery - CRS & HIPEC
Live demonstration PIPAC
Hands on peritonectomy & HIPEC (Wet Lab - Limited Seats)
Symposia on targeted therapy in Ovarian & Colorectal Cancers
HIPEC machine - Technical aspects
Surgical videos
Preoperative optimization & nutrition
Comprehensive review of recent evidence on PSM and HIPEC
MDT case management with interactive voting on key topics
Year in review:
Ÿ Gynecologic Oncology
Ÿ Colorectal Cancer
Best Oral & Poster presentation awards (5 in each category)
International travel fellowships for Best Oral & Poster awardees
5 CME credit points
Highlights
rd3 INTERNATIONAL COURSE
WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY COLORECTAL CANCER
19 - 21 April 2019, Mumbai
2
rd3 INTERNATIONAL COURSE
WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY COLORECTAL CANCER
19 - 21 April 2019, Mumbai
INTERNATIONAL FACULTY
Dr. Vahan Kepenekian
Department of Surgical Oncology, CHU Lyon Sud, University of Lyon,
France
Dr. Vic Verwaal
Dr. Kusamura Shigeki Dr. Henk Schreuder
HIPEC Specialist,Department of GI SurgeryAarhus University Hospital,
Denmark
HIPEC Specialist,IRCCS Foundation National
Cancer Institute, Milan,Italy
Ass. Professor MD, PhD,Gynaecologies Oncologist at
University Medical Center,Utrecht, Netherlands
1
rd3 INTERNATIONAL COURSE
WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY COLORECTAL CANCER
17:20 - 17:50 Panel Discussion on PARP Inhibition in Ovarian Cancer
Shona NagModerator:
: Amit Agarwal, Govind Babu, Rama Joshi,Panelists
Sachin Hingmire, Sudeep Gupta, Sabhayta Gupta,
Satinder Kaur, Somashekhar SP
17:50 - 18:10 Positive Biosciences - Myriad
BRCA Testing – Indian Scenario Myriad
Speaker: Karla Bowles
18:10 - 18:40 ISPSM GBM
19:30 Onwards Cultural Program & Dinner at Terrace Garden, ITC Grand
Central, Parel, Mumbai
Kavya Ajit & Band
Session 12: Industry Symposiums
1
Scientific Program - Day 3 Sunday 21 April 2019, Mumbai
The Year That Was (TYTW) - Gynecological Cancers (Hall A)
Session 13: Quiz for PG students
Time Topic
08:00 - 08:45 JudgesCoordinators
Elizabeth VallikadK ChitratharaAmrit Gupta
Jaya GhoshSeema Gulia
Session 14: Preventive and Primary Care
08:45 - 08:55
Chairpersons : Janmejaya Mohapatra, Elizabeth Vallikad
Reviewer: Neha Kumar
08:45 - 09:45
rd3 INTERNATIONAL COURSE
WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES
YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY COLORECTAL CANCER
Abstract 1Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women.Laniewski P, et al., Sci Rep 2018; 8: 7593
Abstract 2Relationship between the Cervical Microbiome, HIV Status and Precancerous Lesions. Klein C, et al.,MBio. 2019 Feb 19;10(1)
Abstract 3Hand-to-genital and genital-to-genital transmission of human papillomaviruses between male and female sexual partners (HITCH): a prospective cohort study. Talía Malagón et al., Lancet Infect Dis 2019
Abstract 4Five-Year risk of cervical precancer following p16/Ki-67 dual-stain triage of HPV-positive women. Megan A. Clarke, et al., JAMA Oncol. 2019;5(2):181-186
Abstract 5Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Nicole J Polman, et al.,Lancet Oncol. 2019 Feb;20(2):229-238
1
Master
Sudeep Gupta
Scientific Program - Day 3 Sunday 21 April 2019, Mumbai
08:55 - 09:05
09:05 - 09:15
Reviewer: Veena Ranjan
Reviewer: Vinotha Thomas
Time Topic
Abstract 6Trends in human papillomavirus vaccine types 16 and 18 in Cervical precancers, 2008–2014Nancy M. McClun, et al.,Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):602-609
Abstract 7Screening for cervical cancer: US preventive services task force recommendation statement. Curry SJ, et al.,JAMA. 2018 Aug 21;320(7):674-686
Abstract 8Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the us preventive services task force. Melnikow J, et al., JAMA. 2018 Aug 21;320(7):687-705
Abstract 9Association between polycystic ovary syndrome and cancer risk. Yin W1, et al.,JAMA Oncol. 2019 Jan 1;5(1):106-107
Abstract 10Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. Lisa Iversen, et al.,BMJ. 2018 Sep 26;362:k3609
Abstract 11Risk of malignant ovarian cancer based on ultrasonography findings in a large unselected population. Smith-Bindman R, et al.,JAMA Intern Med. 2019 Jan 1;179(1):71-77
Abstract 12Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. Froyman W, et al.,Lancet Oncol. 2019 Mar;20(3):448-458
Abstract 13US preventive services task force recommendation statement. Screening for ovarian cancerJAMA. 2018; 319(6):588-594
The Year That Was (TYTW) - Gynecological Cancers (Hall A)
1
Scientific Program - Day 3 Sunday 21 April 2019, Mumbai
WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES
YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY COLORECTAL CANCER
Reviewer: Rohit Ranade
Abstract 1Correlation between surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.Ramez N. Eskander, et al.,Gynecol Oncol. 2018 Jun;149(3):525-530
Abstract 2A phase III randomized controlled trial of secondary surgical cyto reduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study. Robert L Coleman, et al.,ASCO 2018,JCO.2018.36.15_suppl.5501
Abstract 3A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms.philipp Harter, et al.,N Engl J Med. 2019 Feb 28;380(9):822-832
Abstract 4Hyperthermic intraperitoneal chemotherapy in ovarian cancer. Willemien J. van Drier January 18, 2018. N Engl J Med 2018; 378:230-240
The Year That Was (TYTW) - Gynecological Cancers (Hall A)
1
Scientific Program - Day 3 Sunday 21 April 2019, Mumbai
10:00 - 10:10
10:10 - 10:20
Time Topic
Abstract 5Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. Foster JM,et al.,JAMA Netw Open. 2019 Jan 4;2(1):e186847
Reviewer : Amit Agarwal
Abstract 6Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial)Anna Fagotti, et al.,JCO 36, no. 15_suppl (May 20 2018) 5516-5516
Abstract 7Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602Takachi Onda,et al.,JCO 36, no. 15_suppl (May 20 2018) 5500-5500
Abstract 8Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.Ignace Vergote, et al.,Lancet Oncol. 2018 Dec;19(12):1680-1687
Reviewer: Sachin Hingmire
Abstract 9AGO OVAR 2.21. A prospective randomized Phase III trial of Carboplatin / Gemcitabine / Bevacizumab vs. Carboplatin / Pegylated Liposomal Doxorubicin / Bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. An ENGOT / GCIG Trial.ESMO 2018,Abstract 933OJ. Pfisterer, et al.,Annals of Oncology (2018) 29 (suppl_8): viii332-viii358
Abstract 10Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: A randomized clinical trial. Falchook G, et al.,JAMA Oncol. 2019 Jan 1;5(1):e183773
The Year That Was (TYTW) - Gynecological Cancers (Hall A)
1
Scientific Program - Day 3 Sunday 21 April 2019, Mumbai
10:20 - 10:30
Time Topic
rd3 INTERNATIONAL COURSE
WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES
YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY COLORECTAL CANCER
Abstract 11Paclitaxel with and without pazopanib for persistent or recurrent ovariancancer: A randomized clinical trial.Debra L., et al.,JAMA Oncol. 2018; 4(2):196-202
Abstract 12Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Vergote I, et al.,Gynecol Oncol. 2018 Sep;150(3):471-477
Reviewer: Sandeep Batra
Abstract 13Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.Moore K, et al., N Engl J Med. 2018 Dec 27;379(26):2495-2505
Abstract 14Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial Michael Friedlander, et al.,Lancet Oncol. 2018 Aug;19(8):1126-1134
Abstract 15Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2018. Amit M Oza, et al.,Lancet Oncol. 2018 Aug;19(8):1117-1125
Abstract 16TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort. Panagiotis A,et al., ASCO 2018,Abstract 106.JCO 36, no. 15_suppl (May 20 2018) 106-106
The Year That Was (TYTW) - Gynecological Cancers (Hall A)
1
Scientific Program - Day 3 Sunday 21 April 2019, Mumbai
10:30 - 10:40
10:40 - 11:15
Time Topic
11:15 - 11:30 Tea/Coffee Break
Session 16: Uterine Cancer
Reviewer: Sudeep Gupta
Abstract 17BRCA Challenge: BRCA exchange as a global resource for variants in BRCA1 and BRCA2.Cline MS, et al.,PLoS Genet. 2018 Dec 26;14(12):e1007752.
Abstract 18Accurate classification of BRCA1 variants with saturation genome editing.Gregory M. Findlay, et al.,Nature. 2018 Oct;562(7726):217-222
Abstract 19Molecular profiling of ovarian germ cell tumors.M. Stasenko, et al.,SGO 2018,Abstract 42
Panel Discussion Moderators: Senthil Rajappa, Yogesh KulkarniPanelists: Schreuder Henk, T P Sahoo, G S Bhattacharyya, Hemant Malhotra, Govind Babu, Seema Gulia, Kusamura Shigeki, Harshad Parasnis, Prashant Nyati
11:30 - 11:45
Chairpersons: S K Shrivastava, Prachi Thakar, Geetha Balsarkar11:30 - 12:35
Reviewer: Ranu Patni
Abstract 1Association of endometrial cancer risk with postmenopausal bleeding in women: A systematic review and meta-analysis.Clarke MA,et al., JAMA Intern Med. 2018 Sep 1;178(9):1210-1222
Abstract 2Evaluation of liquid from the papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.Wang Y,et al.,Sci Transl Med. 2018 Mar 21;10(433)
The Year That Was (TYTW) - Gynecological Cancers (Hall A)
1
Scientific Program - Day 3 Sunday 21 April 2019, Mumbai
11:45 - 11:55
11:55 - 12:05
Time Topic
rd3 INTERNATIONAL COURSE
WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES
YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY COLORECTAL CANCER
Abstract 3Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial.Frumovitz M, et al.,Lancet Oncol. 2018 Oct;19(10):1394-1403
Abstract 4Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?F.J. Backes, et al. Gynecologic Oncology 149:7-8.June 2018 (SGO 2018)
Abstract 5GOG 244, the lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients.J.W. Carlsona, et al.,Abstract 11,SGO 2018
Reviewer: Kaustav Talapatra
Abstract 6Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. PORTEC study group.de Boer SM,et al., Lancet Oncol. 2018 Mar;19(3):295-309
Abstract 7Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203.Jklopp AH,et al.,J Clin Oncol. 2018 Aug 20;36(24):2538-2544
Reviewer: Chetan Deshmukh
Abstract 8Single-course methotrexate and single-course combined methotrexate–dactinomycin: A phase III randomized controlled clinical trial in treatment of low-risk gestational trophoblastic neoplasm.L. Chena, et al., Gynecologic Oncology 149:20.June 2018.(SGO 2018)
The Year That Was (TYTW) - Gynecological Cancers (Hall A)
1
12:35 - 12:45
Chairpersons: J N Kulkarni, Jita Parija, Latha Balasubramani12:35 - 13:50
Scientific Program - Day 3 Sunday 21 April 2019, Mumbai
12:05 - 12:35
Time Topic
Session 17: Cervical Cancer
Abstract 9The impact of uterine re-curettage on the number of chemotherapy courses in treatment of post molar gestational trophoblastic neoplasia: A randomized controlled studyR. Hemidaa, et al.,Abstract 41,SGO 2018
Abstract 10TROPHIMMUN, a 2 cohort phase II trial of the anti-PD-L1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia (GTN) patients: preliminary outcomes in cohort A. LYou BM.et al.,BA35, ESMO 2018
Abstract 1Revised FIGO staging for carcinoma of the cervix uteri.Bhatla Net al.,Int J Gynaecol Obstet. 2019 Apr;145(1):129-135.
Abstract 2High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study.Lei J,,et al.,PLoS Med. 2018 Oct 1;15(10)
Abstract 3Circulating human papillomavirus DNA as a biomarker of response in patients with locally advanced cervical cancer treated with definitive chemoradiation.Kathy Han,et al.,JCO Precision Oncology - published online September 13, 2018
The Year That Was (TYTW) - Gynecological Cancers (Hall A)
1
Scientific Program - Day 3 Sunday 21 April 2019, Mumbai
Time Topic
12:45 - 12:55
12:55 - 13:10
rd3 INTERNATIONAL COURSE
WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES
YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY COLORECTAL CANCER
Reviewer: Manas Biswas
Abstract 4LACC trial minimally invasive versus abdominal radical hysterectomy for cervical cancer. november 15, 2018 N Engl J Med 2018. (To also integrate the LACC Abstract IGCS c/o AM & LACC Abstract IGCS c/o AM in the same presentation)Pedro T. Ramirez, et al.,N Engl J Med 2018; 379:1895-1904
Abstract 5Survival after minimally invasive radical hysterectomy for early-stage cervical cancer.Melamed A,et al.,N Engl J Med 2018;379:1905-1914
Abstract 6Outcomes and costs of open, laparoscopic and laparoscopic radical hysterectomy for stage 1B1 cervical cancer.Margul DJ, et al.,Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5502-5502.
Abstract 7Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.Jkim SI, et al.,Gynecol Oncol. 2019 Jan 12.
Reviewer: Supriya Chopra
Abstract 8Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with Stage IB2, IIA, or IIB squamous cervical cancer: A randomized controlled trial.Gupta S, et al. J Clin Oncol. 2018 Jun 1;36(16):1548-1555
Abstract 9Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix: A randomized clinical trialShrivastava S et al.,JAMA Oncol. 2018 Apr 1;4(4):506-513
The Year That Was (TYTW) - Gynecological Cancers (Hall A)
1
Scientific Program - Day 3 Sunday 21 April 2019, Mumbai
Time Topic
13:10 - 13:50
Session 18: Rapid Review
13:50 - 14:00
Chairpersons: Geetha Nagasree, G S Bhattacharyya, Hemant Tongaonkar
13:50 - 14:10
Abstract 10Randomized trial of adjuvant chemotherapy versus concurrent chemoradiotherapy in early-stage cervical cancer after radical surgery: A Chinese Gynecologic Oncology Group study (CSEM-002).D. Wenga, et al. SGO 2018
Abstract 11Association of definitive pelvic radiation therapy with survival among patients with newly diagnosed metastatic cervical cancer.Yuefeng Wang, et al., JAMA Oncol. 2018;4(9):1288-1291.
Abstract 12Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study Hyun Cheol Chung,et al.,Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5522-5522
Panel Discussion Moderator: Amita Maheshwari Panelists: Hemant Tongaonkar, Sudeep Gupta, Supriya Chopra, Chetna Bakshi, Roshni Pande, Yogesh Kulkarni, S K Giri, R A Kerkar, Kedar Deodhar
Reviewer: Sabhyata Gupta
Abstract 1Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing. Lu HM, Li S, Black MH, Lee S, Hoiness R, Wu S, Mu W, Huether R, Chen J, Sridhar S, Tian Y, McFarland R, Dolinsky J, Tippin Davis B, Mexal S, Dunlop C, Elliott A. JAMA Oncol. 2018 Aug 16.
Abstract 2Oral contraceptive use and risks of cancer in the NIH-AARP diet and health study. Michels KA, Brinton LA, Pfeiffer RM, Trabert B. Am J Epidemiol. 2018 Aug 1;187(8):1630-1641
The Year That Was (TYTW) - Gynecological Cancers (Hall A)
1
Abstract Numbering
Scientific Program - Day 3 Sunday 21 April 2019, Mumbai
Time Topic
14:00 - 14:10
rd3 INTERNATIONAL COURSE
WORKSHOP & CONFERENCE ON PERITONEAL SURFACE MALIGNANCIES
YEAR IN REVIEW: GYNECOLOGIC ONCOLOGY COLORECTAL CANCER
Abstract 3Hormone replacement therapy after Oophorectomy and breast Cancer risk among BRCA1 mutation carriers.Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group. JAMA Oncol. 2018 Aug 1;4(8):1059-1065
Abstract 4Different menopausal hormone regimens and risk of breast cancer. Brusselaers N, Tamimi RM, Konings P, Rosner B, Adami HO, Lagergren J.Ann Oncol. 2018 Aug 1;29(8):1771-1776.
The Year That Was (TYTW) - Gynecological Cancers (Hall A)
1
14:30 Onwards
Reviewer: Seema Gulia
Abstract 5Oncological management and obstetric and neonatal outcome5 for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Jorine de Haan, Magali Verheecke, Kristel Van Calsteren, Ben Van Calster, Roman G Shmakov, Mina Mhallem Gziri, and others. The Lancet Oncology, Vol. 19, No. 3, p337–346
Abstract 6Fertility preservation in patients with cancer: ASCO clinical practice guideline update. Kutluk Oktay, Brittany E. Harvey, Ann H. Partridge, Gwendolyn P. Quinn, Joyce Reinecke, Hugh S. Taylor, W. Hamish Wallace, Erica T. Wang, Alison W. Loren. JCO JUL 2018
Abstract 7Outpatient talc administration by Indwelling pleural catheter for malignant effusion. Rahul Bhatnagar, Ph.D April 5, 2018 N Engl J Med 2018; 378:1313-1322
Abstract 8Association between ultraprocessed food consumption and risk of mortality among middle-aged adults in france. Schnabel L, Kesse-Guyot E, Allès B, Touvier M, Srour B, Hercberg S, Buscail C, Julia C. JAMA Intern Med. 2019 Feb 11.
Awards Distribution & Valedictory Lunch
14:10 - 14:30
Scientific Program - Day 3 Sunday 21 April 2019, Mumbai
Time Topic
08.00- 08:40 Free Papers
Judges: A S Ramakrishnan, Pravin Kammar, Anil Heroor
Shivendra Singh
08:40 - 09:10 Debate on CME (complete mesocolic excision) for Colon Cancer